Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

ADHD drugs and cardiovascular risk.

Nissen SE.

N Engl J Med. 2006 Apr 6;354(14):1445-8. Epub 2006 Mar 20. No abstract available.

2.

ADHD drugs and cardiovascular risk.

Rappley MD, Moore JW, Dokken D.

N Engl J Med. 2006 May 25;354(21):2296-8; author reply 2296-8. No abstract available.

PMID:
16729375
3.

To box OR NOT TO box.

Newstadt M.

J Ky Med Assoc. 2006 Aug;104(8):344-5. No abstract available.

PMID:
16939037
4.

FDA ponders cardiovascular risks of ADHD drugs.

Young D.

Am J Health Syst Pharm. 2006 Mar 15;63(6):492-4. No abstract available.

PMID:
16522874
5.

Debate over warnings for ADHD stimulants.

[No authors listed]

Child Health Alert. 2006 Apr;24:1. No abstract available.

PMID:
16673500
6.

ADHD drugs and cardiovascular risk.

Anders T, Sharfstein S.

N Engl J Med. 2006 May 25;354(21):2296-8; author reply 2296-8. No abstract available.

7.

Update on adult attention-deficit/hyperactivity disorder.

Hammerness P, Surman C, Miller K.

Curr Neurol Neurosci Rep. 2008 Nov;8(6):484-9.

PMID:
18957185
8.

Medications for attention deficit hyperactivity disorder: cardiovascular concerns.

Wooltorton E.

CMAJ. 2006 Jul 4;175(1):29. Epub 2006 Jun 13. No abstract available.

9.

[Medication for ADHD and the risk of cardiovascular mortality].

Langendijk PN, Wilde AA.

Ned Tijdschr Geneeskd. 2006 Aug 5;150(31):1713-4. Dutch.

PMID:
16924941
10.

Stimulant medications and attention deficit-hyperactivity disorder.

Cohen AL, Jhung MA, Budnitz DS.

N Engl J Med. 2006 May 25;354(21):2294-5. No abstract available.

11.

FDA-approved drugs to treat ADHD.

[No authors listed]

J Psychosoc Nurs Ment Health Serv. 2012 Mar;50(3):11-2. doi: 10.3928/02793695-20120127-01. No abstract available.

PMID:
22390784
12.

Cardiovascular safety of medication treatments for attention-deficit/hyperactivity disorder.

Newcorn JH, Donnelly C.

Mt Sinai J Med. 2009 Apr;76(2):198-203. doi: 10.1002/msj.20096. No abstract available.

PMID:
19306385
13.

US senator alleges FDA tried to prevent Adderall XR withdrawal in Canada.

Eggertson L.

CMAJ. 2005 Mar 29;172(7):865. Epub 2005 Mar 9. No abstract available.

14.

Attention-deficit hyperactivity disorder (ADHD) treatment and sudden death.

Besag FM.

Drug Saf. 2009;32(11):1097-100. doi: 10.2165/11530340-000000000-00000. No abstract available.

PMID:
19810781
15.

Cardiovascular safety of ADHD medication treatments.

Newcorn JH.

CNS Spectr. 2008 Oct;13(10 Suppl 15):5-8. No abstract available.

PMID:
18955948
16.

[Sympathomimetics in ADHD. Cardiovascular risks, FDA warns].

Ostman-Smith I, Dellborg M.

Lakartidningen. 2007 Apr 25-May 1;104(17):1307. Swedish. No abstract available.

PMID:
17547274
17.

Stimulants and sudden death: what is a physician to do?

Wilens TE, Prince JB, Spencer TJ, Biederman J.

Pediatrics. 2006 Sep;118(3):1215-9. Review.

PMID:
16951018
18.

Phenylpropanolamine and stroke: the study, the FDA ruling, the implications.

Mersfelder TL.

Cleve Clin J Med. 2001 Mar;68(3):208-9, 213-9, 223. Review.

PMID:
11263849
19.

Stimulant treatment of ADHD and risk of sudden death in children.

Vitiello B, Towbin K.

Am J Psychiatry. 2009 Sep;166(9):955-7. doi: 10.1176/appi.ajp.2009.09050619. Epub 2009 Jun 15. No abstract available.

PMID:
19528196
20.

Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls.

Daughton JM, Kratochvil CJ.

J Am Acad Child Adolesc Psychiatry. 2009 Mar;48(3):240-8. doi: 10.1097/CHI.0b013e318197748f. Review. No abstract available.

PMID:
19242289

Supplemental Content

Support Center